Alvotech And Teva's Selarsdi™ (ustekinumab-aekn), Bio

According to an April 2024 press release, Alvotech and Teva's Selarsdi™ (ustekinumab-aekn) was approved by the FDA on April 16 as a biosimilar of Janssen / Johnson & Johnson's Stelara® (ustekinumab).

Related Keywords

California , United States , Carlton , Georgia , American , Gina Bertolini , Stephen Page , Foley Lardner , Sarah Hogan , Sheppard Mullin Richter Hampton , American Health Law Association , Akin Gump Strauss Hauer Feld , Us Department Of Justice , Columbus Regional Healthcare System Inc , Health Care , Subcommittee On Primary Health , Senate Health , California Office Of Health Care Affordability , Life Sciences , Human Service Office , Inspector General , Health Care Contracts , Clause By Guide , Sarah Staples Carlton , Health Care Affordability , Regional Healthcare System , Senators Edward Markey , Elizabeth Warren , Primary Health , Retirement Security , Mondaq , Alvotech And Teva Amp 39s Selarsdi X2122 Ustekinumab Aekn , Iosimilar To Stelara Xae Approved By Fda , Food , Drugs , Healthcare , Food And Drugs Law , Iotechnology Amp Nanotechnology , Intellectual Property , Patent , ,